NCT06042387Recruiting
Genome Analysis Across Populations in Inflammatory Bowel Disease
Source: ClinicalTrials.gov · Last updated 9 Oct 2026
Brief summary (registry, in English)
Objective: To use clinical, genetic and genome analysis to better understand and define the genetic and environmental factors that contribute to IBD within affected populations.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 150 (estimated)
- First submitted
- 31 May 2023
- Start date
- 1 May 2022
- Primary completion date
- May 2027
- Lead sponsor
- Mount Sinai Hospital, Canada
- Diseases
- Crohn's disease, Ulcerative colitis
- NCT number
- NCT06042387
What you commit to
- Study type: Observational
- Planned participants: 150
- From 1 May 2022 to the primary completion date, May 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- \- Subjects with other gastrointestinal conditions not meeting the above IBD or Healthy Control criteria
Who the study is looking for
- Subjects: diagnosed with Inflammatory Bowel Disease (Crohn's disease, ulcerative colitis, IBD-undetermined)
- Available medical records to confirm IBD diagnosis (Crohn's disease, Ulcerative colitis, IBD undetermined (IBD-U))
- Healthy controls: no personal history of IBD, no family history of IBD, no history of unexplained chronic diarrhea/blood in stool/anemia/abdominal pain/weight loss
- Any age
Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Sinai Health System Coordinator of this site? Confirm its status | Toronto | Canada | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.